Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook

Cantor Notes PRE’s ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company’s Financial Position

Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus

CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that Cantor Fitzgerald has reiterated its Overweight rating on the Company in its latest equity research report dated November 11, 2025, while updating its 12-month price target to $31, compared to its prior target of $32. Cantor noted that this adjustment reflects valuation model updates related specifically to the Company’s planned divestment of its Europa business, with no change to its core investment thesis on Prenetics.

In its report, Cantor highlights the Company’s strong operating execution and IM8’s accelerating performance:

• 3Q25 revenue of $23.6 million, representing ~568% year-over-year growth
• IM8 revenue of $17.2 million, up ~76% sequentially with ~60% gross margins
• Customer payback period of ~3.9 months and 80%+ subscription rate
• ~387 BTC held as of November 10 (~$41 million), contributing to total liquidity of approximately $120 million
• Cantor forecasts FY2026 revenue of approximately $217 million, reflecting continued IM8 momentum and international scale-up
  

Cantor continues to view Prenetics as undervalued, noting PRE trades at just 0.7× EV/2026E revenue, compared to approximately 1.1× for consumer-health peers.

Cantor’s Price Target Evolution Throughout 2025

• September 16, 2025: Price target increased from $14 → $26 following strong 2Q25 performance
• October 28, 2025: Price target increased from $26 → $32 following $44 Million Equity Offering
• November 11, 2025: Price target updated to $31, driven solely by model adjustments tied to the upcoming Europa divestment, with Cantor reiterating its Overweight rating and long-term positive view on IM8 and Prenetics’ growth strategy
  

Management Commentary

Danny Yeung, CEO of Prenetics, commented:

“Cantor’s continued research coverage further underscores our emergence as a global leader in health and longevity. As IM8 scales across multiple international markets, the conviction from a respected institution like Cantor strengthens our position and widens investor understanding of the magnitude of the opportunity ahead.”